Inhibikase Therapeutics (IKT) EBITDA Margin Growth (1y) (2021 - 2023)
Inhibikase Therapeutics (IKT) EBITDA Margin Growth (1y) (2021 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1,552.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1,536.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -170.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1,276.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -44.03 Bn |
| Sep 30, 2023 | 5.59 Mn |
| Jun 30, 2023 | 6.55 Mn |
| Mar 31, 2023 | 277,384.00 |
| Dec 31, 2022 | 25.25 Mn |
| Sep 30, 2022 | -6.05 Mn |
| Jun 30, 2022 | -7.06 Mn |
| Mar 31, 2022 | -989,489.00 |
| Dec 31, 2021 | -25.86 Mn |
| Sep 30, 2021 | 40,022.00 |
| Jun 30, 2021 | -433.00 |
| Mar 31, 2021 | 1,286.00 |